The nanocomplex delivery of MALAT1 targeting siRNA in glioblastoma patients increased the sensitivity of the tumor to temozolomide (TMZ) treatment [168], while a novel ASO drug against non-coding mitochondrial RNA demonstrated good tolerance in a phase one clinical study [169,170]. Here, MALAT1 is linked to neoplasm.